Presentations

Recent presentations and scientific papers. Presentations are in Adobe Acrobat format unless otherwise noted.

Scientific Presentations

High Rate of Sustained Virologic Response in Patients with HCV Genotype-1A Infection: A Phase 2 Trial of Faldaprevir, Deleobuvir and PPI-668, with and without Ribavirin (EASL, April 2014)

PPI-668, A Potent New Pan-Genotypic HCV NS5A Inhibitor: Phase 1 Efficacy and Safety (AASLD, November 2012)

Identification and Characterization of PPI-383, a Next Generation HCV NS5B Non-Nucleoside Inhibitor with Potent Activity Against All Major HCV Genotypes (EASL, April 2012)

Dose Ranging Trial of PPI-461, a Potent New Pan-Genotypic HCV NS5A Inhibitor, in Patients with HCV Genotype-1 Infection (AASLD, November 2011)

Safety and Pharmakinetics of PPI-461 : A Potent HCV NS5A Inhibitor with Pan-Genotype Activity (AASLD, April 2010)

Resistance Monitoring of HCV Patients Treated for Three Days with the NS5A Inhibitor PPI-461 Reveals Rapid Emergence of HCV Variants (AASLD, November 2010)

Identification and Characterization of PPI-461, a Potent and Selective HCV NS5A inhibitor with Activity Against all HCV Genotypes (EASL, April 2010)

Identification and Profile of Potent and Selective Inhibitors of HS5A HCV Protein (EASL, April 2009)

Advertisements